1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,020 | 1,105 | 18.07. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | WIPO veröffentlicht Patent von Tevogen Bio für KI-gestützte Peptid-Vorhersage | 2 | Investing.com Deutsch | ||
| Fr | Tevogen Bio's AI-powered peptide prediction patent published by WIPO | 1 | Investing.com | ||
| Fr | Tevogen Bio Inc: Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides | 55 | GlobeNewswire (Europe) | WARREN, N.J., July 18, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) announced today that the International Bureau of the World Intellectual Property Organization... ► Artikel lesen | |
| Do | Tevogen Bio Inc: Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility | 1 | GlobeNewswire (USA) | ||
| Mi | Tevogen Bio Inc: Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell Alpha Launch | 1 | GlobeNewswire (USA) | ||
| Mo | Tevogen Bio Inc: Tevogen.AI Builds Alpha Version of PredicTcell Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs | 114 | GlobeNewswire (Europe) | Tevogen.AI's model drastically reduces target analysis and has the potential to generate billions in cost savings across the healthcare system by streamlining early-stage drug discovery, reducing... ► Artikel lesen | |
| 10.07. | Tevogen Bio Inc: Tevogen's New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation | 280 | GlobeNewswire (Europe) | CEO's personal contribution fully funds build-out and first-year operationsDoubled HQ footprint centralizes cross-functional teams, including research, regulatory affairs, and the expanding Tevogen.AI... ► Artikel lesen | |
| TEVOGEN BIO Aktie jetzt für 0€ handeln | |||||
| 10.07. | Tevogen Bio Holdings stattet CEO mit 8 Millionen Restricted Shares aus und aktualisiert Aktienanzahl | 4 | Investing.com Deutsch | ||
| 10.07. | Tevogen Bio Holdings Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.07. | Tevogen Bio Holdings schließt Aktienemissionsvertrag über 50 Millionen US-Dollar ab | 6 | Investing.com Deutsch | ||
| 30.06. | Tevogen Bio Holdings Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.06. | Tevogen Bio Inc: Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters | 1 | GlobeNewswire (USA) | ||
| 23.06. | Tevogen Bio Holdings Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.06. | Tevogen files to sell 30.73M shares of common stock for holders | 2 | Seeking Alpha | ||
| 18.06. | Tevogen Bio Inc: Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery | 250 | GlobeNewswire (Europe) | WARREN, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today provided an update on its ongoing development of a cytotoxic T lymphocyte (CTL)... ► Artikel lesen | |
| 09.06. | Tevogen Bio Inc: Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives | 2 | GlobeNewswire (USA) | ||
| 03.06. | Tevogen Bio erweitert Bürofläche in New Jersey durch wichtigen Nachtrag | 3 | Investing.com Deutsch | ||
| 03.06. | Tevogen Bio Holdings Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.05. | Tevogen Bio erweitert KI-Initiative in der Immuntherapie-Entwicklung | 5 | Investing.com Deutsch | ||
| 30.05. | Tevogen Bio expands AI in immunotherapy development | 1 | Investing.com |
1 2 3 4 5 Weiter >>
99 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,405 | -0,35 % | Dividendenbekanntmachungen (10.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,48 USD 1,2626 EUR AT&T INC US00206R1023 0,2775 USD 0,2367 EUR AZZ INC US0024741045 0,2 USD 0,1706... ► Artikel lesen | |
| AMGEN | 253,90 | +0,10 % | Amgen: Robustes Pharma-Geschäft und Dividende | Die Amgen-Aktie stellt eine attraktive Depotbeimischung für jedes diversifizierte oder Pharma-orientierte Anlegerdepot dar. Die Bewertung ist vergleichsweise günstig, die Aussichten stabil. Und es gibt... ► Artikel lesen | |
| NOVAVAX | 6,025 | -0,05 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| PALATIN TECHNOLOGIES | 0,134 | -1,03 % | Palatin Technologies, Inc.: Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity | Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatment
Combination of oral PL7737 and tirzepatide resulted in additive... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 466,50 | -0,04 % | Regeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold? | ||
| INOVIO PHARMACEUTICALS | 1,230 | +1,65 % | INOVIO Pharma Announces Proposed Public Offering | WASHINGTON (dpa-AFX) - INOVIO Pharmaceuticals Inc. (INO) announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof)... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 3,360 | +7,01 % | COSCIENS Biopharma Inc.: COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders | TORONTO, ONTARIO, June 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) ("COSCIENS" or the "Company"), a life sciences company developing and commercializing a diversified... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 50,10 | +1,62 % | BioMarin: Wolfe Research bestätigt Outperform-Rating trotz neuer Konkurrenz im PKU-Markt | ||
| NUREXONE BIOLOGIC | 0,443 | -1,56 % | ExoPTEN zeigt vielversprechende Ergebnisse bei Rückenmarksverletzungen | ||
| ARROWHEAD PHARMACEUTICALS | 14,450 | +0,28 % | Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results | PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting... ► Artikel lesen | |
| XOMA ROYALTY | 22,000 | 0,00 % | ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction | SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC and BOSTON and EMERYVILLE, Calif., July 14, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,076 | +9,88 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 2,440 | +0,41 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort | -Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in fourth cohort, permitting dose escalation in expected final cohortMarlborough, Massachusetts--(Newsfile Corp. -... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report |
Das Unternehmen TEVOGEN BIO HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,190 Euro und damit +11,74 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TEVOGEN BIO HOLDINGS INC finden Sie auf Wallstreet Online.